| NCT ID | NCT06374368 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ostrava |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2019-05-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2019-05-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In an effort to replicate metabolic surgery's durable results in metabolic disease while minimizing its risks, two innovative methods has been created. Two surgical methods to create a bowel-to-bowel anastomosis, similar to the type used in current metabolic surgeries. It be to create a jejuno-ileal, side-to-side anastomosis and jejunocolic side-to-side anastomosis. The side-to-side jejuno-ileal anastomosis and side-to-side jejunocolic anastomosis provides two routes for ingested food. The new, shorter route has a malabsorptive effect similar to that seen in Roux en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) - procedures which leads to weight loss. Additionally, delivery of non-absorbed macronutrients to the distal ileum, or transverse colon can enhance incretin effect and improve Type 2 Diabetes Mellitus parameters. However, the native route is also preserved, which theoretically reduces the risk of malnutrition, diarrhea, and metabolic derangements seen in other metabolic surgeries.The side-to-side jejuno-ileal anastomosis was already tested in the Pilot Study of the GI Windows Self-Forming Magnetic (SFM) Anastomosis Device for Creation of an Incisionless Small Bowel Bypass for Treatment of Obesity and Diabetes in year 2015 (15). The results of this study demonstrated the safety of this approach without serious adverse events. This non-surgical approach resulted in significant weight loss, favorable changes in insulin and incretin responses to a mixed meal and significant improvement in HbA1c in T2DM (16).In summary, metabolic diseases are a growing pandemic with suboptimal clinical solutions. The surgical side-to-side jejuno-ileal anastomosis and side-to-side jejuno-colic anastomosis without gastrectomy potentially represents a new class of therapy that may produce durable clinical results generally associated with surgery while minimizing its attendant risks.
Eligibility Criteria
Inclusion Criteria: * age 18-65 years at screening; * Body mass index ≥30 or ≤50kg/m2; * If subject has Type 2 Diabetes: fasting plasma glucose greater than 6,1 mmol/l at time of enrollment if not treated with anti-diabetic medication; * If on no diabetes medications, Hemoglobin A1C between and including 6.5 and 9.0 at time of enrollment. Exclusion Criteria: * Body Mass Index \>50 or \<30 kg/m2; * Diagnosis of Type 2 diabetes less than 6 months; * History of suspected gastrointestinal disease (for example cirrhosis, inflammatory bowel disease); * History of active malignancy (not in remission) with the exception of squamous or basal cell carcinoma of the skin; * Ongoing systemic infection; * Chronic pancreatitis; * Chronic liver disease of any cause; * Poorly controlled psychiatric disease (for example ongoing major depression, schizophrenia, borderline personality, suicidality, psychosis); * Any history of an eating disorder within the past 5 years; * Pre-existing severe comorbid cardio-respiratory disease (for example congestive heart failure, cardiac arrhythmia, coronary artery disease, chronic obstructive lung disease, pulmonary embolism); * uncontrolled hypertension (systolic Blood Preassure \> 150 mm Hg or diastolic Blood Preassure \> 100 mm Hg).
Contact & Investigator
Marek Bužga, Doc.
PRINCIPAL INVESTIGATOR
University of Ostrava
Frequently Asked Questions
Who can join the NCT06374368 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06374368 currently recruiting?
Yes, NCT06374368 is actively recruiting participants. Contact the research team at jana.soldanova@osu.cz for enrollment information.
Where is the NCT06374368 trial being conducted?
This trial is being conducted at Ostrava, Czechia, Ostrava, Czechia.
Who is sponsoring the NCT06374368 clinical trial?
NCT06374368 is sponsored by University of Ostrava. The principal investigator is Marek Bužga, Doc. at University of Ostrava. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.